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SurvivalAbstract Background: Age-related breast cancer treatment variance is widespread with
many older women having primary endocrine therapy (PET), which may contribute to inferior
survival and local control. This propensity-matched study determined if a subgroup of older
women may safely be offered PET.
Methods: Multicentre, prospective, UK, observational cohort study with propensity-matched
analysis to determine optimal allocation of surgery plus ET (SþET) or PET in women aged
70 with breast cancer. Data on fitness, frailty, cancer stage, grade, biotype, treatment and
quality of life were collected. Propensity-matching (based on age, health status and cancer
stage) adjusted for allocation bias when comparing SþET with PET.
Findings: A total of 3416 women (median age 77, range 69e102) were recruited from 56 breast
unitsd2854 (88%) had ERþ breast cancer: 2354 had SþET and 500 PET. Median follow-up
was 52 months. Patients treated with PET were older and frailer than patients treated with
SþET. Unmatched overall survival was inferior in the PET group (hazard ratio, (HR) 0.27,
95% confidence interval (CI) 0.23e0.33, P < 0.001). Unmatched breast cancerespecific sur-
vival (BCSS) was also inferior in patients treated with PET (HR: 0.41, CI: 0.29e0.58,
P < 0.001 for BCSS). In the matched analysis, PET was still associated with an inferior overall
survival (HR Z 0.72, 95% CI: 0.53e0.98, P Z 0.04) but not BCSS (HR Z 0.74, 95% CI: 0.40
e1.37, PZ 0.34) although at 4e5 years subtle divergence of the curves commenced in favor of
surgery. Global health status diverged at certain time points between groups but over 24
months was similar when adjusted for baseline variance.
Interpretation: For the majority of older women with early ERþ breast cancer, surgery is on-
cologically superior to PET. In less fit, older women, with characteristics similar to the
matched cohort of this study (median age 81 with higher comorbidity and functional impair-
ment burdens, the BCSS survival differential disappears at least out to 4e5 year follow-up,
suggesting that for those with less than 5-year predicted life-expectancy (>90 years or >85
with comorbidities or frailty) individualised decision making regarding PET versus SþET
may be appropriate and safe to offer. The Age Gap online decision tool may support this de-
cision-making process (https://agegap.shef.ac.uk/).
Trial registration number: ISRCTN: 46099296.
ª 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Breast cancer is a common disease in older women with
a third of cases occurring in women over 70 years of age.
Overall mortality is higher among these women, but is
commonly attributable to other causes than breast
cancer. A US study found breast cancer to be the pri-
mary cause of death in just 23% of patients that died in
their 80s, compared to 96% in women with breast cancer
who died aged under 40. Breast cancerespecific mor-
tality rates are also higher in older women, which may
be due to later stage at diagnosis and suboptimal
treatment. However, it is important to avoid over-
treatment in the very frail for what may be an indolent
disease in a patient with a very limited life expectancy[2]. Treatment needs to be tailored to health status,
disease characteristics and patient preferences.
Surgery may be unnecessary for some frailer older
women as short- and medium-term disease control may
be achieved by use of anti-oestrogens (primary endo-
crine therapy, PET). In addition, the resilience of frailer
older women to standard cancer treatments may be
reduced, leading to a long-term deterioration of their
functional capacity. Older women place a higher value
on maintenance of independence and quality of life [3]
compared to younger women, so they may prefer
slightly less effective anticancer treatment to maintain
disability-free life expectancy and quality of life [4].
A systematic review of randomised controlled trials
(RCTs) evaluating the role of surgery versus PET
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treatments but inferior local control with PET [5]. Only
one of the trials exclusively recruited women with
ERþ breast cancer, and this trial demonstrated no
survival advantage for surgery at 10 years [6]. An update
of one of the trials with 28 years follow-up showed no
survival advantage to surgery when all trial participants
had died [7]. A recent patient-level meta-analysis of the
data from these trials with longer-term follow-up
demonstrated a significant survival benefit from surgery.
The included trials were flawed, as they did not stratify
patients according to age, fitness (all were fit for surgery
under general anaesthesia) or tumour biology (particu-
larly the ER), which may permit the identification of
subgroups of women who may not benefit from surgery.
They also did not restrict recruitment to women with
ERþ cancer (the trials predated routine testing), so the
PET group likely had 10e17% [1] of women who
effectively had no active therapy, which will bias
outcome towards surgery. Analysis of cohorts of women
with strongly ERþ cancers treated with PET suggests
that there is no survival advantage from surgery [8]. No
study has looked at composite measures of health and
tumour biology to select patients for surgery or PET.
A further complicating factor is that all of the RCTs
used tamoxifen as the anti-oestrogen in both the SþET
and PET arms, whereas in modern practice aromatase
inhibitors (AIs) are the preferred and more effective
option [9]. PET may therefore be more efficacious if
potential candidates are selected appropriately based on
their health status and tumour biology and treated with
AIs rather than tamoxifen. A previous randomised
clinical trial (ESTEEM) attempted such health status
stratification but failed to recruit due to lack of patient
and clinician equipoise [10].
The purpose of this study was to use real-world,
prospectively collected, observational data and adjust
for allocation bias using propensity score matched
analysis. This sought to identify whether PET may be
appropriate for a subgroup of less fit, older women with
ERþ breast cancer.Methods
Ethics approval
Ethics (IRAS: 12 LO 1808) and research governance
approvals were obtained. All patients (or their proxies, if
cognitively impaired) gave written informed consent.
Study design
It was a prospective, multicentre, observational cohort
study. Patients could participate at three levels: full,
partial (no requirement to complete quality-of-life as-
sessments) or proxy (third-party data collection ifcognitively impaired). Study reporting is in line with
STROBE guidelines [11].
Sites
Patients were recruited from 56 UK breast units in
England and Wales (Supplemental Table ST1).
Inclusion criteria
Female patients aged 70 years at the time of breast
cancer diagnosis. Primary unilateral or bilateral oper-
able invasive breast cancer (TNM stages: T1-3 and some
T4b, N0-2, M0).
Exclusion criteria
Inoperable diseaseand previous breast cancer within 5
years were considered exclusion criteria. Patients lacking
cognitive capacity as defined by the Mental Capacity
Act were eligible if a friend or relative was willing to sign
proxy consent. Surgery could be performed under local
or general anaesthesia.
Baseline data collection
Women were recruited at the time of breast cancer
diagnosis, before commencement of treatment.
At baseline women underwent health assessment
using validated tools including:
1. Comorbidities (Charlson comorbidity index (CCI) [12]),
2. Nutrition (Abridged Patient Generated Subjective Global
Assessment (aPG-SGA) [13]),
3. Physical functioning (Activities of Daily Living (ADL)
[14]),
4. Complex physical functioning (Instrumental Activities of
Daily Living (IADL) [15]),
5. Cognitive status (Mini Mental State Examination (MMSE
[16], under licence),
6. Eastern Cooperative Oncology Group Performance Status
(ECOG-PS) [17].
7. Medications.
In addition, quality of life was assessed at baseline
using the European Organisation for Research and
Treatment of Cancer Quality of Life Questionnaires
(EORTC-QLQ)-C30 [18], a generic quality of life tool
and health utility by the EQ-5D-5L [19] to monitor
functional decline. (A more detailed analysis of quality-
of-life outcomes are reported separately.)
Baseline cancer data were collected including: cancer
type, grade, nodal status, primary size (clinical and on
imaging), oestrogen, progesterone and Her-2 receptor
status, and Oncotype DX score (if available). Staging
for metastatic disease was performed if clinically indi-
cated but otherwise presumed M0.
Fig. 1. STROBE diagram of patient recruitment and dispositions.
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Table 1
Patient and cancer characteristics at baseline. Unmatched.
PET Surgery Total
N Z 500 N Z 2354 N Z 2854
Age n 500 2354 2854
Mean (SD) 83.5 (6.5) 76.4 (5.1) 77.6 (6.0)
Median (IQR) 84 (79, 88) 76 (72, 80) 77 (73, 82)
Min, Max 70, 102 69, 94 69, 102
aPG-SGA score n 322 2021 2343
Mean (SD) 2.3 (3.1) 1.2 (2.2) 1.4 (2.4)
Median (IQR) 1.0 (0.0, 3.0) 0 (0.0, 2.0) 0 (0.0, 2.0)
Min, Max 0, 18 0, 17 0, 18
Barthel
ADL index
n 399 2135 2534
Mean (SD) 88.8 (16.6) 97.7 (6.2) 96.3 (9.3)
Median (IQR) 95 (85.0, 100.0) 100 (100.0, 100.0) 100.0 (95.0, 100.0)
Min, Max 5, 100 10, 100 5, 100
IADL index n 382 2104 2486
Mean (SD) 6.1 (2.1) 7.6 (0.9) 7.4 (1.3)
Median (IQR) 7.0 (5.0, 8.0) 8.0 (8.0, 8.0) 8.0 (7.0, 8.0)
Min, Max 0, 8 0, 8 0, 8
Modified CCI n 459 2273 2732
Mean (SD) 5.8 (2.0) 4.3 (1.4) 4.5 (1.6)
Median (IQR) 6 (4.0, 7.0) 4 (3.0, 5.0) 4.0 (3.0, 5.0)
Min, Max 3, 17 3, 13 3, 17
MMSE n 273 1631 1904
Mean (SD) 26.7 (3.7) 28.3 (2.5) 28.1 (2.8)
Median (IQR) 28 (26.0, 29.0) 29 (28.0, 30.0) 29.0 (27.0, 30.0)
Min, Max 10, 30 10, 30 10, 30
Number
of current medications
n 450 2050 2500
Mean (SD) 5.0 (3.0) 4.1 (2.6) 4.2 (2.7)
Median (IQR) 5.0 (3.0, 7.0) 4.0 (2.0, 5.0) 4.0 (2.0, 6.0)
Min, Max 0, 18 0, 18 0, 18
aPG-SGA
risk category
n 376 2109 2485
Low 291 (77.4%) 1848 (87.6%) 2139 (86.1%)
Moderate 62 (16.5%) 227 (10.8%) 289 (11.6%)
High 23 (6.1%) 34 (1.6%) 57 (2.3%)
ADL
risk
category
n 408 2172 2580
No dependency 191 (46.8%) 1684 (77.5%) 1875 (72.7%)
Mild dependency 53 (13.0%) 258 (11.9%) 311 (12.1%)
Moderate/severe dependency 164 (40.2%) 230 (10.6%) 394 (15.3%)
IADL
risk category
N 403 2158 2561
No dependency 158 (39.2%) 1759 (81.5%) 1917 (74.9%)
Mild dependency 64 (15.9%) 193 (8.9%) 257 (10.0%)
Moderate/severe dependency 181 (44.9%) 206 (9.5%) 387 (15.1%)
MMSE
risk category
n 464 2286 2750
Normal function 339 (73.1%) 2037 (89.1%) 2376 (86.4%)
Mild impairment 75 (16.2%) 206 (9.0%) 281 (10.2%)
Moderate impairment 20 (4.3%) 29 (1.3%) 49 (1.8%)
Severe 30 (6.5%) 14 (0.6%) 44 (1.6%)
How many clinically involved
nodes were detectable?
n 483 2309 2792
Mean (SD) 0.2 (0.6) 0,2 (0.8) 0.2 (0.7)
Median (IQR) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
Min, Max 0, 4 0, 20 0, 20
Size (mm) n 487 2318 2805
Mean (SD) 23.9 (12.0) 19.2 (12.3) 20.0 (12.4)
Median (IQR) 21.0 (16.0, 30.0) 17.0 (11.0, 24.0) 18.0 (12.0, 25.0)
Min, Max 0, 70 0, 150 0, 150
Nottingham Prognostic Index n 456 2172 2628
Mean (SD) 3.5 (0.8) 3.5 (0.8) 3.5 (0.8)
Median (IQR) 3.4 (3.2, 3.9) 3.3 (3.2, 4.0) 3.4 (3.2, 4.0)
Min, Max 2.1, 7 2, 6.7 2, 7
Side of primary tumour n 500 2354 2854
Right 223 (44.6%) 1084 (46.0%) 1307 (45.8%)
Left 277 (55.4%) 1270 (54.0%) 1547 (54.2%)
Her 2 Score n 359 1911 2270
Negative 311 (86.6%) 1641 (85.9%) 1952 (86.0%)
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Table 1 (continued )
PET Surgery Total
N Z 500 N Z 2354 N Z 2854
Inconclusive 14 (3.9%) 70 (3.7%) 84 (3.7%)
Positive 34 (9.5%) 200 (10.5%) 234 (10.3%)
Provisional histological grade n 484 2243 2727
Grade 1 98 (20.2%) 399 (17.8%) 497 (18.2%)
Grade 2 329 (68.0%) 1475 (65.8%) 1804 (66.2%)
Grade 3 57 (11.8%) 369 (16.5%) 426 (15.6%)
Type of hormone therapy (for PET, at 6-weeks
time point, for surgery at 6-months time point)
n 500 2354 2854
Letrozole 414 (82.8%) 981 (41.7%) 1395 (48.9%)
Anastrazole 31 (6.2%) 782 (33.2%) 813 (28.5%)
Tamoxifen 22 (4.4%) 269 (11.4%) 291 (10.2%)
Exemestane 7 (1.4%) 35 (1.5%) 42 (1.5%)
Missing 26 (5.2%) 287 (12.2%) 313 (10.9%)
Abbreviations. aPG-SGA: abridged patient generated subjective global assessment. ADL: activities of global living. IADL: instrumental activities
of global living. MMSE: mini mental state examination. CCI: Charlson comorbidities index. ECOG-PS: Eastern cooperative oncology group
performance status. NPI: Nottingham prognostic index. SD: Standard deviation. IQR: interquartile range.
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conserving surgery (BCS) (wide excision, therapeutic
mammoplasty) and mastectomy (þ/ reconstruction).
Axillary surgery was categorised into no axillary
surgery (NS), sentinel lymph node biopsy (SLNB, axil-
lary sample) and axillary node clearance (ANC). Post-
operative histology was recorded for patients undergo-
ing surgery. Detailed reporting of surgery types and
outcomes are reported separately [20].
Use of radiotherapy and systemic therapy (types and
adverse events) was recorded when used in the SþET
patient cohort as part of standard care.Fig. 2. Temporal summary of surgically treated patients and the adjuvant
treatment targets the majority of women had their surgery between b
adjuvant endocrine therapy at their 6-week follow-up visit. Radiothe
number of women had neoadjuvant chemotherapy starting between ba
started it between 6 weeks and 6 months. These timelines are importan
functional outcomes.Survival and recurrence outcomes
Patients were followed up at 1.5, 6, 12, 18 and 24
months. All patients were assessed for evidence of local,
regional or metastatic recurrence at each visit both
clinically and using appropriate imaging and biopsy
techniques depending on the location of recurrence.
Progression was defined using the RECIST criteria
(response evaluation criteria in solid tumours [21]) for
PET patients to allow us to accurately define when local
failure occurred. The time to progression and the time to
metastatic progression were both calculated startingtherapies they received at each follow-up time point. In line with UK
aseline and 6 weeks, with many commencing their post-surgical
rapy was usually given between 6 weeks and 6 months. A small
seline and 6 weeks, but the majority of those having chemotherapy
t for understanding the impact of therapies on quality of life and
Table 2
Covariate balance in the final matched dataset: Surgery (plus adjuvant therapies) versus primary endocrine therapy (PET).
Surgery PET
N Z 422 N Z 238
Age n 422 238
Mean (SD) 80.57 (5.36) 81.30 (5.94)
Median (IQR) 81.00 (76.00, 84.00) 82.00 (77.00, 85.75)
Min, Max 70, 94 70, 96
aPG-SGA Low 343 (81.3%) 190 (79.8%)
Moderate 62 (14.7%) 39 (16.4%)
High 17 (4.0%) 9 (3.8%)
ADL No dependency 271 (64.2%) 134 (56.3%)
Mild dependency 54 (12.8%) 34 (14.3%)
Moderate/severe dependency 97 (23.0%) 70 (29.4%)
iADL No dependency 250 (59.2%) 124 (52.1%)
Mild dependency 73 (17.3%) 38 (16.0%)
Moderate/severe dependency 99 (23.5%) 76 (31.9%)
MMSE Normal function 351 (83.2%) 191 (80.3%)
Mild impairment 60 (14.2%) 39 (16.4%)
Moderate
impairment
8 (1.9%) 6 (2.5%)
Severe 3 (0.7%) 2 (0.8%)
CCI 0 312 (73.9%) 161 (67.6%)
2 110 (26.1%) 77 (32.4%)
ECOG-PS Low 370 (87.7%) 194 (81.5%)
Moderate 36 (8.5%) 27 (11.3%)
High 16 (3.8%) 17 (7.1%)
Medications 3 or fewer 176 (41.7%) 100 (42.0%)
4 or more 246 (58.3%) 138 (58.0%)
NPI Moderate 217 (51.4%) 125 (52.5%)
Good 194 (46.0%) 107 (45.0%)
Poor 11 (2.6%) 6 (2.5%)
Abbreviations. aPG-SGA: abridged patient generated subjective global assessment. ADL: activities of global living. IADL: instrumental activities
of global living. MMSE: mini mental state examination. CCI: Charlson comorbidities index. ECOG-PS: Eastern cooperative oncology group
performance status. NPI: Nottingham prognostic index. SD: Standard deviation. IQR: interquartile range.
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recorded recurrence were censored at the date of last
tumour assessment.
Deaths were adjudicated as breast cancer related or
other causes blind to treatment. Survival outcomes were
obtained directly via follow-up to 2 years and beyond 2
years via the UK cancer registry (with consent) and
patient notes. Overall survival (OS) was defined as the
time from initial assessment to death or censored at the
date last known to be alive, and breast cancerespecific
survival (BCSS) was defined as the time from initial
assessment to breast cancer death, or censored either at
the date of non-breast-cancer death or the date last
known to be alive.
Adverse events
Complications were categorised using Common Termi-
nology Criteria for Adverse Events [22] system
(CTCAE) grouped into systemic (atelectasis, stroke,
infarction, DVT/embolism, arrhythmia, allergic reaction
and somnolence) and local (lymphoedema, neuropathy,
functional difference, wound pain, wound necrosis,
infection, haematoma/haemorrhage, seroma)
complications.Quality of life
Quality of life was recorded in fully participating pa-
tients at baseline and at 1.5, 6, 12, 18 and 24 months
using the validated EORTC tools listed above which
were scored according to the EORTC Scoring Manuals
(3rd Edition [23]) and reference publications. Partially
completed items were managed according to the
EORTC manual recommendations. In addition, the EQ-
5D-5L score was assessed at each visit to monitor health
utility with particular emphasis on functional outcomes,
which are of particular importance to women in this age
group [24] as older women may lack resilience.Functional resilience following surgery
Several domains in the quality-of-life tools reflect func-
tional status including 3 in the EQ-5D and items 1e7 in
the EORTC-QLQ-C30. These were assessed at baseline
and at intervals after breast cancer treatment to deter-
mine the resilience of these older women to therapy.
Data from patients with a complete series of scores at
all-time points were compared at baseline and follow-
up, to determine the functional impacts of treatments.
Fig. 3. a-h. Kaplan Meier overall survival (a and b), breast cancerespecific survival (c and d), recurrence-free survival curves (e and f) and
metastatic recurrence-free survival (g and h) for unmatched (a, c, e and g) and matched (b, d, f and h) populations in women treated with
surgery plus adjuvant endocrine therapy versus PET. Median follow-up of 52 months shown. Confidence intervals shown in pale blue or
orange shading. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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Analyses were performed in IBM SPSS version 24 (IBM
Corp, NY), R version 3.6.3 and Stata (StataCorp LLC).
Propensity matching
Logistic regression was used to calculate propensity
scores for treatment allocation, which were used to
match PET to SþET patients. The covariates were
measures of functionality (ADL, IADL, MMSE,
ECOG), nutritional status (abridged PG-SGA),
comorbidities (CCI, number of medications) and age.
The ratio and calliper widths of the propensity
scores were chosen based on examination ofpropensity score overlaps for several combinations of
ratios and callipers (to describe how closely matched
the patients are). A 1:2 ratio for PET to surgery and a
calliper of 0.25 times the propensity scores’ standard
deviation were used to optimally match quality and
numbers. Participants were also matched by Not-
tingham Prognostic Index (NPI) [25] category (good
3.4, moderate 3.5e5.4, poor >5.4) to avoid fit
participants with aggressive cancer being matched
with frail participants with smaller cancers.
For both OS and BCSS, four Cox proportional
hazard models were fitted to compare treatments on the
entire unmatched cohort. The first two included all pa-
tients, both unadjusted and then adjusted for baseline
L. Wyld et al. / European Journal of Cancer 142 (2021) 48e6256age, functionality and tumour characteristics, allowing
us to give estimates for the whole group whilst still
adjusting for these covariates. The last two included
only matched patients and incorporated a shared frailty
term (random effect) for matching, again both adjusted
and unadjusted. The primary analysis was on the
matched population as this related to a subgroup for
whom either treatment may have been considered.
Results
Cohort description
The study recruited 3416 women between January 2013
and June 2018, with a median age of 77 years (range
69e102; 5 patients were recruited just before their 70th
birthday and have been retained in the study). Of these
3315 were fully eligible for analysis (Fig. 1). The ma-
jority (2854; 86%) had ERþ breast cancer on biopsy and
were therefore potential candidates for PET or SþET.
The following results relate to patients with ERþ breast
cancer only.
Of the 2854 patients with ERþ cancer, 2354/2854
(82%) had SþET (60% breast conservation and 40%
mastectomy) and 500/2854 (18%) commenced PET (87%
with letrozole) within 6 months of baseline assessment.
Tumour, patient and treatment characteristics are
summarised in Table 1. Patients undergoing SþET were
generally younger, fitter and had superior function
compared to those undergoing PET.
Women in the SþET group had various additional
therapies including radiotherapy, chemotherapy and
trastuzumab according to clinical indications at various
time points (Fig. 2).
Propensity matching
Table 2 shows the balance of characteristics achieved in
the final matched dataset, which found a suitable match
for 238 (48%) of the PET patients, 184 of whom were
matched with two surgery patients and 54 matched to
only one. The remaining 262 PET patients comprised
201 patients with incomplete functional data (117 (58%
were partial/consultee participants and therefore too
frail to complete questionnaires) and a further 61 that
were too dissimilar from patients undergoing surgery
(again largely too frail and comorbid for any surgery). A
summary of the matching process and matching quality
are summarised in Supplemental Fig. SF1.
Overall survival and breast cancerespecific survival
Overall survival among all patients (unmatched analyses)
Overall mortality status at median 52 months follow-up
was available for 2793/2854 (98%) patients in the SþET
and PET populations.Of the 486 patients who received PET and with sur-
vival data, 203 (41.8%) died during follow-up, compared
to 336/2307 (14.6%) of SþET patients. Patients treated
with PET had inferior overall survival compared with
those treated with SþET (unadjusted HR 0.27, 95% CI
0.23e0.33, P < 0.001) (Fig. 3 and Table 3) but,
adjusting for case mix via multivariable Cox regression
reduced this difference (adjusted HR Z 0.83, 95% CI:
0.63e1.09, P Z 0.18) (Fig. 3 and Table 3).
Breast cancerespecific survival (unmatched analyses)
A total of 45/476 (9.5%) patients died due to breast
cancer in the PET group versus 113/2293 (4.9%) in the
surgery group (unadjusted HR: 0.41, CI: 0.29e0.58,
P < 0.001). Patients treated with PET had inferior BCSS
compared with those treated with SþET, but adjusting
for case mix reduced this difference to a hazard ratio of
0.89 (95% CI: 0.52 to 1.53; P Z 0.68; Fig. 3 and Table
3).
Overall survival (matched analyses)
Mortality status was available for 643/660 (97%) pa-
tients in the matched surgery versus PET population. Of
the 229 patients who received PET and for whom we
had adequate data for analysis, 79/229 (34.5%) died
during follow-up from all causes, compared to 106/414
(25.6%) of surgery patients (matched, unadjusted
HR:0.66, 95% CI: 0.49e0.90, P Z 0.008). Matched
patients treated with PET had inferior overall survival
compared with those treated with SþET. Further
adjusting for case mix reduced but did not remove this
difference (matched, adjusted HR: 0.72, 95% CI:
0.53e0.98, P Z 0.037) (Fig. 3 and Table 3).
Breast cancerespecific survival (matched analyses)
In the matched breast cancerespecific mortality cohort
there were 17/223 (7.6%) breast cancerespecific deaths for
PET versus 27/408 (6.6%) for surgery (matched, unad-
justed HR: 0.80, 95% CI: 0.43e1.47, PZ 0.46). Adjusting
for residual imbalance via multivariable regression pro-
vided similar findings (matched, adjusted HR: 0.74, 95%
CI: 0.40e1.37, PZ 0.34) (Fig. 3 and Table 3).
The various match/unmatched, adjusted and unad-
justed hazard ratios are summarised in Supplemental
Table ST2.
Recurrence and progression
Unmatched analyses
Rates of overall (locoregional and metastatic) recur-
rence in the unmatched cohort were higher in patients in
the PET group 33/451 (7.3%) compared to the SþET
group 113/2325 (4.9%). Of these locoregional re-
currences (or progression in the case of PET) there were
6/451 (1.33%) for PET and 25/2325 (1.07%) for SþET
(Table 3 and Fig. 3). After adjusting for age, baseline
health status, physical function and NPI, surgery had no
Fig. 4. Mean global health status and 95% confidence intervals for women treated with PET versus Surgery plus endocrine therapy in the
unmatched cohort.
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0.52e1.95; P Z 0.981).
Matched analysis
On matching, difference in rates of recurrence were not
significant and the hazard ratio for recurrence between
the two treatments was 1.11 (95% CI: 0.55e2.26),
P Z 0.775 (Table 3 and Fig. 3).Quality of life
The global health score of the EORTC QLQ C30
(questions 29 and 30)
Significant variation in age and health status meant that
baseline quality-of-life scores differed. Patients treated
surgically reported higher QoL both at baseline and
throughout the 24-month follow-up. Between baseline and
6 weeks (when the majority of patients started treatment
with either surgery or PET, Fig. 2) a clinically significantreduction inmeanglobal health statuswasobserved froma
mean of 66.2 (standard deviation 21.1) to 61.5 (21.4) for
PETpatients and from77.1 (17.8) to 70.8 (18.5) for surgery
patients. In neither group did levels recover to baseline
following treatment even at 2 years (Table 4 and Fig. 4).Functional independence after treatment
The EQ-5D-5L score was compared in the unmatched
cohort. Baseline scores demonstrated significant varia-
tion. Both the overall score and the individual questions
showed decreased health status across the 2-year period.
For the PET group the fall was gradual whereas for the
surgery group there was an early sharp fall between
baseline and 6 weeks which then failed to recover,
indicating a lack of resilience in this older population.
This was particularly evident in the ‘ability to perform
usual activities score’ shown in Fig. 5.
Table 3
Overall and breast cancerespecific survival and recurrence data for the unmatched and matched cohorts.
Total cohort Unmatched Matched
PET Surgery PET Surgery
N Z 500 N Z 2354 N Z 238 N Z 422
Overall survival Data available 486 2307 229 414
Alive 351 (72.2%) 2095 (90.8%) 150 (65.5%) 308 (74.4%)
Died of any cause 135 (27.8%) 212 (9.2%) 79 (34.5%) 106 (25.6%)
Cause-specific survival Data available 477 2297 223 408
Alive or died of other causes 452 (94.8%) 2217 (96.5%) 206 (92.4%) 381 (93.4%)
Died of breast cancer 25 (5.2%) 80 (3.5%) 17 (7.6%) 27 (6.6%)
Recurrence (all types) Data available 451 2325 221 417
No 418 (92.7%) 2212 (95.1%) 210 (95.0%) 392 (94.0%)
Yes 33 (7.3%) 113 (4.9%) 11 (5.0%) 25 (6.0%)
Metastatic recurrence Data available 450 2324 221 417
No 423 (94.0%) 2236 (96.2%) 211 (95.5%) 399 (95.7%)
Yes 27 (6.0%) 88 (3.8%) 10 (4.5%) 18 (4.3%)
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This is reported in detail elsewhere [20]. There was one
death within 30 days of surgery which was due to met-
astatic breast cancer, though surgery cannot be ruled
out as contributing. There was one further death at day
72, which was due to COPD and pneumonia. There
were therefore no deaths directly attributable to surgery.
Surgical morbidity was moderate. There were 551/
2854 (19%) complications although most were local
wound complications such as seroma, haematoma and
infection with only 59/2854 (2.1%) women sufferingTable 4
Global health score of the EORTC QLQ C30 score for matched and unm
Unmatched
Global health status/QoL Baseline n
Mean (SD)
6 weeks n
Mean (SD)
6 months n
Mean (SD)
12 months n
Mean (SD)
18 months n
Mean (SD)
24 months n
Mean (SD)
Matched
Global health status/QoL Baseline n
Mean (SD)
6 weeks n
Mean (SD)
6 months n
Mean (SD)
12 months n
Mean (SD)
18 months n
Mean (SD)
24 months n
Mean (SD)systemic complications such as cardiorespiratory, cere-
brovascular or thrombotic events.
Discussion
The aim of the Age Gap study was to determine the
outcomes of PET versus SþET. As expected, patient
characteristics differed significantly between groups with
PET generally allocated to older, frailer women. There is
significant variation in practice with respect to surgery
rates across the UK [26]. This variance meant we were
able to identify cohorts of women with similar charac-
teristics who were treated with PET or SþET permittingatched patients at each time point.
PET Surgery Total
258 1644 1902
66.2 (21.1) 77.1 (17.8) 75.6 (18.7)
230 1511 1741
61.5 (21.4) 70.8 (18.5) 69.6 (19.2)
199 1418 1617
63.5 (19.5) 70.7 (19.3) 69.8 (19.5)
149 1233 1382
59.2 (18.6) 72.1 (18.4) 70.7 (18.9)
109 1033 1142
60.2 (21.7) 71.1 (19.3) 70.0 (19.8)
82 902 984
60.6 (20.6) 70.3 (19.6) 69.5 (19.8)
PET Surgery Total
151 293 444
69.1 (19.5) 73.4 (18.5) 71.9 (18.9)
139 259 398
64.1 (20.9) 66.8 (19.1) 65.9 (19.8)
122 236 358
64.2 (18.7) 64.5 (19.4) 64.4 (19.1)
96 206 302
58.9 (18.9) 67.2 (18.4) 64.6 (19.0)
68 175 243
62.5 (22.0) 66.5 (20.4) 65.4 (20.9)
50 147 197
63.3 (19.6) 63.0 (21.3) 63.1 (20.8)
Fig. 5. Bar charts of the EQ-5D-5L ‘ability to perform usual activities’ score at each time point for the surgery versus PET population for
the unmatched population.
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women who may have been candidates for either treat-
ment. Some degree of bias inevitably persists due to
imperfections in the matching process, but this study
achieved a good quality match. As a result, whilst sur-
gery is still associated with an overall survival benefit,
this difference disappears in both BCSS and recurrence/
progression-free survival out to 52 months follow-up.
The rate of local recurrence/progression was low in
both arms, and for the PET group the rate of progres-
sion is lower than other reported series. This may reflect
lack of direct follow-up out to 52 months as directly
collected data were only available to 24 months. It may
also reflect the fact that the cohort selected for PET were
all women with ERþ cancers and letrozole was mainly
used, which is more effective than tamoxifen.In this large cohort, surgery was the primary treat-
ment modality in 83% and PET in 17%, which is slightly
lower than a recent national audit (National Audit of
Breast Cancer in Older People, NABCOP [27]) which
reported a PET rate of 24%. This variance may reflect a
difference in mix of unit practice, selective recruitment
of the less frail into the trial or the technical challenge of
recruiting women having PET where the recruitment
window before treatment starts is narrow. As seen in
Fig. 1, 156 eligible patients were missed due to
commencing treatment before they could be recruited,
the majority of whom would have been started on PET.
The age range of patients within the study is not entirely
representative of the UK population of women with
breast cancer, with a slight excess of younger women
and fewer of the very oldest. In addition, the rate of
L. Wyld et al. / European Journal of Cancer 142 (2021) 48e6260study discontinuation was slightly higher in the older
age groups. This reduces the generalisability of the
study.
This study suggests that older women with a short
life-expectancy of 5 years or less derive little or no sur-
vival benefit from undergoing surgery, but women likely
to survive longer than 5 years may start to see endocrine
resistance develop on PET. This accords with the RCTs
where survival outcomes at 5 years were equivalent but
over the longer term outcomes diverge. The data from
our study have an advantage over the historic RCT data
in that all women in this analysis had ERþ cancer, the
majority were treated with aromatase inhibitors, which
are more effective in the neoadjuvant and PET settings,
and have the real-world age, comorbidity and frailty
characteristics typical of PET patients in clinical
practice.
Of great interest in this study was the impact of
treatment on quality of life and physical function. In the
unmatched analysis it is clear that women in the PET
treatment group have worse baseline quality-of-life
scores in most domains, reflecting their greater comor-
bidity and reduced physical function. Analysis of the
global health status score shows that there was a slightly
steeper decline between baseline and 6 weeks in the
surgery group, reflecting the acute impact of surgery.
Furthermore, these scores do not return to baseline thus
demonstrating the longer term impact of a cancer
diagnosis and its treatment. We also see a reduction in
the number of women with no limitations to their ‘usual
activities’ with the EQ-5D after surgery, which never
recovers even after 24 months denoting a lack of resil-
ience in this older age group. This should be taken into
account when making clinical decisions concerning
frailer, older women.
Previous work by this group has shown that older
women value quality of life and independence highly in
their treatment decision making [3,24]. These women
perceive PET to offer a safe option to maintain the
status quo and minimise risk.
There were no deaths directly attributable to surgery,
in keeping with other national audits and severe surgical
morbidity was low (2.1% had systemic morbidity such as
cerebrovascular or thrombotic complications), reflecting
the fact that breast surgeons may exclude the frailest
older women from surgery if they have ERþ cancer by
offering PET. Higher rates of adverse events are re-
ported when frail older women have breast surgery. Two
women died within 90 days of surgery of non-surgical
causes and whilst these deaths cannot be attributed to
surgery they probably represent surgical overtreatment.
For women in the matched cohort (generally older,
less fit women), the benefits of surgery at 5 years were
very small and diminish for women with greater age/
frailty and comorbidity burdens (i.e. women too unfit to
match to anyone in the surgery cohort).One of the key aims of this work was to identify if a
subgroup of women may safely be offered PET. The
data suggest this is the case, although longer-term
follow-up will be required. It is still likely, provided
patients are fit enough, that surgery will give optimal
survival for the majority of older women. Women who
are of borderline fitness for surgery should be offered an
informed choice, highlighting the potential difference in
survival and adverse events. To this end, our group has
developed the fully validated [28] Age Gap Decision
Tool (https://agegap.shef.ac.uk/) using UK cancer
registry data. The tool has been developed with older
women for usability and acceptability [29,30]. This
tool may support shared decision making in older
women.
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